GX CN BIOTECH Stock (02820.HK) Real-time Quotes - Financial Data - Analyst Ratings

Company Encyclopedia

GX CN BIOTECH

02820.HK

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

Innovent, Takeda Close $11.4 Bln Collaboration To Advance Next-Generation IO And ADC Therapies

Innovent Biologics and Takeda have finalized a $11.4 billion global strategic collaboration to advance next-generation immuno-oncology and antibody-drug conjugate therapies. The partnership includes co-development and commercialization of IBI363 in the U.S., with Takeda holding exclusive rights outside Greater China. Takeda also gains rights to IBI343 and an option for IBI3001. Innovent receives a $1.2 billion upfront payment, potential milestone payments, and royalties, with shared profits for IBI363 in the U.S.

rttnews·8 Hours ago

Innovent Biologics Closes Strategic Partnership with Takeda

Innovent Biologics has closed a global strategic partnership with Takeda, fulfilling their License, Option, and Collaboration Agreement, and Share Issuance Agreement. This led to the issuance of 6,913,834 shares, raising approximately HK$778 million. The partnership enhances Innovent's strategic positioning and financial resources for developing biologic medicines. The latest analyst rating for Innovent's stock (HK:1801) is a Hold with a HK$101.00 price target. Innovent Biologics focuses on innovative therapies in the pharmaceutical industry.

Tip Ranks·Yesterday at 07:11

Tip Ranks·Yesterday at 07:11